cancer

Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer

Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy

A big step forwards in the management of muscle invasive bladder cancer in which platinum cannot be used has been taken in the KEYNOTE-905 study of perioperative antibody drug conjugate thereapy with

Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting

bart-neyns-md-phd-injectng-cells-into-cranial-cavity-for-recurrent-glioblastoma-long-survival

Stacey Kenfield and June Chan UCSF

Jonathan T Yang, MD, PhD

“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time i

Andy Zeng, Toronto: Transcriptome Map Key to Malignant Transformation in AML

SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a

NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weil

The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease — MCD — could soon be treatable following findings announced at the American Society of Hematology annual meeting

NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast

LONDON—Inequalities in cancer care delivery and overall spending have had a big impact on cancer survival rates in Europe, according to Michel Coleman, Professor of Epidemiology and Vital Statistics a

Val Curtis Global Handwashing Day is October 15th, 2008: an opportunity to remind everybody that millions of lives, especially children’s lives, can be saved by avoiding diarrhoea and other dise

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin In this edition Peter Goo

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod

Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F

Giovanni Apolone In this edition of Audio News, presented by Peter Goodwin, Giovanni Apolone (Mario Negri Institute, Milan) and Stuart Pocock (London School of Hygiene and Tropical Medicine), talk abo

Giorgio Scagliotti Robert Pirker GIORGIO SCAGLIOTTI, University of Turin ROBERT PIRKER, Medical University of Vienna A heated debate took place at the European Congress on Lung Cancer in Turin between

Nick Thatcher NICK THATCHER, Christie Hospital, Manchester There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cance

Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He t

Silvia Novello SILVIA NOVELLO, University of Turin Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello w

Christian Manegold Nick Thatcher Christian Manegold, Heidelberg University Medical Center, Manheim Nick Thatcher, Christie Hospital, Manchester Is bevacizumab a new standard of care for patients with

Volume 16 Number 6 (March 15th, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) American Society of Hematology Annual Meeting (December 8-11, 2007

Kenneth Anderson Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston Multiple myeloma may soon be consi

David Cunningham REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 DAVID CUNNINGHAM, Royal Marsden Hospital, London The oral agent capeticabine

Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro

Robert Mayer ROBERT MAYER, Dana-Farber Cancer Institute, Boston One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some

Charles Hsu CHARLES HSU, Johns Hopkins University, Baltimore Big improvements in overall survival were achieved by combining radiation with adjuvant chemotherapy for patients with pancreas cancer in a

Jack Cuzick JACK CUZICK, Wolfson Institute of Preventive Medicine, London New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continu

Jose Baselga JOSE BASELGA, Vall d’Hebron Hospital, Barcelona RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The in

Susan O’Brien SUSAN O’BRIEN, MD Anderson Cancer Center, Houston For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamid

Richard Stone RICHARD STONE, Dana-Farber Cancer Institute, Boston GEORGE CANELLOS, Dana-Farber Cancer Institute New data shows that dasatinib is giving durable responses in patients with chronic phase

Jonathan Kolitz JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY GEORGE CANELLOS, Dana-Farber Cancer Institute For patients with acute myeloid leukemia in first remission, new data suggests tha

Jean-Yves Douillard Gordon McVie REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 Р27 September 2007 JEAN-YVES DOUILLARD, Centre Ren̩ Gauducheau, N

Nicholas James Gordon McVie REFERENCE: Abstract: 3LB (Presidential Session), ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 NICHOLAS JAMES, Birmingham University COMM

Jose Baselga Gordon McVie REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona CO

Pierre Guillou David Jayne REFERENCE: J Clin Oncol 25:3061-3068 PIERRE GUILLOU, St James’ Hospital, Leeds COMMENT: DAVID JAYNE, St James’ Hospital, Leeds Laparoscopic-assisted resection fo

Pierre Laurent-Puig Bill Hait REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris COMMEN

Paul Fisher REFERENCE: Meet the Professor Session, AACR 2007, Los Angeles PAUL FISHER, Columbia University, New York Patients with cancer could soon be treated with adenoviruses capable of infecting b

Alberto Sobrero Cetuximab With Irinotecan: Phase III Study Shows Benefit in Patients with Oxaliplatin-Refractory Colorectal Cancer REFERENCE: ABSTRACT LB-2; AACR 2007, Los Angeles, Plenary Session ALB

Lorie Hughes Rachel Ellsworth Rowan Chlebowski Victor Vogel Local Excision Alone for Selected Patients with Ductal Carcinoma In Situ? REFERENCE: Abstract: 29 LORIE HUGHES, The Hope Center, Cartersvill

IAN SMITH, Royal Marsden Hospital, London REFERENCE: Lancet 369:29 Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in th

Dennis Slamon George Peoples James Holland Massimo Christofanilli Trastuzumab: Mature Results in Early Breast Cancer Show Superiority REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 52

Clifford Hudis Mark Einstein Tony Greco James Berenson Edward Ambinder Breast Cancer: HER2 Still a Useful Target After Trastuzumab Resistance REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 Nov

Robert Ozols William See Ruth Lupu Improving on Standard Treatment in Ovarian Cancer: Have We Hit a Wall? REFERENCE: Abstract 5002, 2006 ASCO Annual Meeting; N Engl J Med 2006, 354:34-43 ROBERT OZOLS,